Dysregulated CD46 signals during the contracting phase prevent normal IFN‐γ shut‐down and the switch into normal Th1 contraction and contribute to disease pathology in RA and multiple sclerosis (MS) 15, 16. This evidence concerns the gene CD46 and myeloid sarcoma.